AI Article Synopsis

  • Gastrointestinal stromal tumors (GIST) are the most common type of mesenchymal tumors in the digestive system, frequently found in the stomach and less often in the jejunum, with jejunal GIST being rare and hard to diagnose, often discovered at an advanced stage.
  • A case study details a 50-year-old woman with metastatic jejunal GIST treated with Imatinib, who subsequently faced acute abdominal issues leading to an emergency surgery for a perforated tumor and complications from TKI treatment.
  • While tyrosine kinase inhibitors are the main therapy for advanced GIST, surgical intervention is necessary for jejunal cases due to their complexity, and medical professionals should be aware of the potential side effects of TKIs in

Article Abstract

Introduction: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract; occurring most often in the stomach and to a lesser extent in the jejunum. The majority of the tumors express activating mutations in either c-KIT or PDGFRA tyrosine kinases, which respond to tyrosine kinase inhibitors (TKI). Jejunal GIST is considered to be extremely rare and challenging to diagnose due to its non-specific presentation. As a result, patients usually present at an advance stage of the disease, making the prognosis poor and difficult to manage.

Case Presentation: In the present study, we report a 50-year-old female who was diagnosed with metastatic jejunal GIST. She was commenced on Imatinib (TKI) and shortly after she presented to the emergency department with an acute abdomen. A CT scan of the abdomen revealed ischemic changes in the jejunal loops and pneumoperitoneum. The patient required emergency laparotomy due to perforated GIST, and creation of pericardial window due to hemodynamic instability possibly secondary TKI-related isolated pericardial effusion.

Conclusion: Jejunal GIST is rare and usually presents as emergency due to obstruction, hemorrhage or rarely perforation. Although, systemic therapy with TKI is the principal treatment for advance disease, Jejunal GIST should be removed surgically. It is surgically challenging due to the anatomical complexity of the tumor. Surgeons treating such patients must be cautious for TKI side effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130195PMC
http://dx.doi.org/10.1016/j.ijscr.2023.108197DOI Listing

Publication Analysis

Top Keywords

jejunal gist
16
acute abdomen
8
gastrointestinal stromal
8
isolated pericardial
8
50-year-old female
8
jejunal
6
gist
6
abdomen secondary
4
secondary perforated
4
perforated jejunal
4

Similar Publications

Article Synopsis
  • * Out of 50 patients, those who had bypass surgery (with gastrojejunostomy) experienced significantly less grade B-C DGE compared to those who didn't, suggesting the bypass may be beneficial.
  • * Although the bypass group showed a trend towards shorter hospital stays, the difference wasn’t statistically significant, indicating further research is needed on the overall benefits of the gastrojejunostomy procedure.
View Article and Find Full Text PDF

Gastrointestinal stromal tumors (GISTs) are rare malignant tumors that arise from the connective tissues of the gastrointestinal tract. Reports about GISTs treated with imatinib for over five years are exceedingly rare. In this case report, we present a patient with GIST who remained alive for two decades after undergoing imatinib treatment.

View Article and Find Full Text PDF

Gastrointestinal bleeding is classified as obscure in 5% of patients who remain symptomatic after undergoing upper endoscopy, colonoscopy, and small bowel capsule endoscopy. We present a case of a 45-year-old male who had obscure bleeding for eight years and presented with hemorrhagic shock. He was found to have an ulcerated intra-luminal jejunal lesion on enteroscopy, then had surgical resection that revealed a low-risk gastrointestinal stromal tumor (GIST).

View Article and Find Full Text PDF
Article Synopsis
  • Gastrointestinal stromal tumors (GIST) are rare tumors affecting about 10 to 15 people per million, primarily found in the stomach and small intestine, and may present symptoms like nausea and abdominal fullness, although 30% are asymptomatic.
  • The standard treatment for GIST is surgical resection with negative margins.
  • A case report describes a 69-year-old woman who experienced severe digestive tract bleeding, leading to the discovery of a GIST in her jejunum during surgery.*
View Article and Find Full Text PDF

Unusual case report of bifocal gastrointestinal stromal tumor in the first jejunal loop uncovered by severe hemorrhage.

Int J Surg Case Rep

November 2024

General Surgery Department, Mahmoud El Matri Hospital, V59M+628, Ariana, Tunisia; Faculty of Medicine of Tunis, University of Tunis El Manar, R534+F9H, Rue de la Faculté de Médecine, Tunis, Tunisia.

Article Synopsis
  • Gastrointestinal stromal tumors (GISTs) are rare tumors in the digestive tract, making up only 1% of gastrointestinal tumors, with jejunal GISTs being even less common.
  • A unique case involved a 60-year-old woman who experienced severe gastrointestinal bleeding due to two jejunal GISTs, which were diagnosed after normal initial endoscopy but confirmed through imaging and jejunoscopy.
  • The case underscores the importance of recognizing rare presentations of GISTs, as well as the need for surgery and advanced diagnostic tools for effective treatment and management.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!